New Chemotherapy Shows Promise for Pancreatic Cancer Survival

Bologna, Italy – February 23, 2026 – A new chemotherapeutic regimen for pancreatic cancer is showing promise in improving patient outcomes, according to research presented and published this month.

A New Approach to a Difficult Cancer

Pancreatic cancer remains one of the deadliest cancers, with limited effective treatment options. The new research, detailed in the prestigious medical journal The Lancet, focuses on a novel chemotherapy combination, dubbed “Paxg,” for patients with borderline-resectable or locally advanced pancreatic adenocarcinoma – a malignant tumor limited to the pancreas or surrounding tissues without distant spread, representing approximately 95% of pancreatic cancer cases.

The Cassandra Trial: Paxg vs. MFolfirinox

The findings stem from the Cassandra trial, a Phase 3 clinical study coordinated by the San Raffaele Hospital in Milan, Italy, with participation from the Sant’Orsola Hospital in Bologna. The study directly compared Paxg to mFolfirinox, the current standard of care for this type of pancreatic cancer. Both regimens are chemotherapy combinations administered to patients prior to surgical removal of the tumor.

Paxg consists of four specific chemotherapeutic drugs, a combination developed at San Raffaele Hospital approximately a dozen years ago. MFolfirinox is an established chemotherapy protocol.

Significant Improvement in Progression-Free Survival

The study revealed a statistically significant improvement in progression-free survival – the length of time patients lived without the cancer worsening – for those treated with Paxg compared to those receiving mFolfirinox. Specifically, progression-free survival was 16 months with Paxg, compared to just over 10 months with the standard treatment. This suggests the new regimen may more effectively control the disease before surgery.

Funding and Future Research

Notably, the research was entirely funded by patient advocacy organizations, highlighting the commitment of patient communities to advancing pancreatic cancer treatment. The Italian Medicines Agency (AIFA) recognized the potential value of the research and transitioned the study from a Phase 2 to a Phase 3 trial, indicating its potential for impacting clinical guidelines.

Researchers are now focused on evaluating long-term survival rates – beyond five years – for patients treated with Paxg. The initial study focused on progression-free survival, and continued follow-up will determine the impact on overall survival.

Implications for Treatment

“The data presented at the annual meeting of the American Society of Clinical Oncology (ASCO) last June in Chicago, suggest we may be on the cusp of a breakthrough in treating these tumors,” explained Mariacristina Di Marco, a researcher at the University of Bologna who collaborated on the trial at the Sant’Orsola Hospital. “While it will take time for these results to be adopted internationally, the magnitude of the difference observed suggests a potential shift in how we approach treatment.”

The research builds on a growing understanding of the benefits of pre-operative chemotherapy for pancreatic cancer. Riccardo Casadei, director of Pancreatic and Endocrine Surgery at Sant’Orsola Hospital, and his team have been early proponents of this approach, and this new data further supports its potential.

New FDA Approval for Locally Advanced Pancreatic Cancer

In related news, the U.S. Food and Drug Administration (FDA) recently approved a new treatment for locally advanced pancreatic cancer. February 17, 2026, the FDA approved Optune Pax®, a wearable medical device delivering Tumor Treating Fields Therapy (TTFields), in combination with gemcitabine and nab-paclitaxel. This marks the first treatment approval in nearly 30 years for this stage of the disease.

Immunotherapy Shows Promise in Select Cases

a UCLA-led study published earlier this month found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic cancer. While the combination didn’t benefit all patients, a subset experienced unusually deep and durable responses, and some were able to undergo surgery as a result. The study, sponsored by the UCLA Health Jonsson Comprehensive Cancer Center, also revealed insights into the tumor’s immune response, potentially paving the way for more refined immunotherapy strategies in the future.

Minimally Invasive Endoscopic Treatment Also Showing Potential

Researchers at WVU Medicine are also exploring a new minimally invasive endoscopic treatment for pancreatic cancer, which is showing early promise. While pancreatic cancer remains a challenging disease, these recent developments offer a glimmer of hope for improved outcomes.

This proves important to remember that these are ongoing areas of research, and treatment decisions should always be made in consultation with a qualified medical professional.